Date: 2014-02-10
Type of information: Collaboration agreement
Compound: in vivo molecular imaging agents
Company: ImaginAb (USA - CA) Duke-NUS Graduate Medical School Singapore (Duke-NUS) (Singapore)
Therapeutic area: Cancer - Oncology - Autoimmune diseases - Technology - Services
Type agreement: collaboration
Action mechanism: imaging agent/radiopharmaceutical
Disease:
Details: * On February 10, 2014, ImaginAb announced that it has entered into a partnership with the Duke-NUS Graduate Medical School Singapore (Duke-NUS) to establish a joint corporate laboratory to develop new in vivo molecular imaging agents to study cancer biology and immune function. ImaginAb is a U.S. clinical-stage company that develops in vivo molecular imaging agents based on a proprietary antibody fragment technology platform. ImaginAb\'s mission is to transform the clinical management of cancer and autoimmune diseases via targeted molecular imaging. Under the terms of the agreement, the parties will establish protein engineering and molecular imaging capabilities designed to interface with Duke-NUS\'s \"Signature Research Programs\" (SRPs) in cancer & stem cell biology, cardiovascular and metabolic diseases, neurobiology and immunology. The new facilities will also be used to support ImaginAb\'s R&D activities. Termed the \"Imaging Biomarker Development Lab\" (IBDL), the joint laboratory is the latest initiative under the National Research Foundation (NRF) Corp Lab @ University scheme. The IBDL program represents a $15 million commitment between ImaginAb, Duke-NUS and the NRF. The laboratory will also be accessible to industry and academic collaborators with the objective of developing precision medicine strategies for the treatment of cancer and immune-mediated diseases. The IBDL will incorporate several specialty core facilities designed to operate in an integrated fashion with Duke-NUS\' existing research services. The IBDL will uniquely feature a state-of-the-art molecular imaging facility, operating within Duke-NUS\'s Specific Pathogen Free (SPF) space, an invaluable resource for immunology-based research.
Financial terms:
Latest news:
